January 2013 in “Dermatology” The ILDS Newsletter reported on efforts to support albinism patients in Tanzania and dermatological conferences.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
22 citations
,
April 2024 in “Indian Journal of Microbiology” July 2025 in “Anais Brasileiros de Dermatologia” The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.
January 2026 in “Frontiers in Bioscience-Landmark” Araliadiol protects skin cells from damage by boosting antioxidant defenses.
November 2025 in “Journal of Investigative Dermatology” Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
January 2026 in “International Journal of Dermatology” The new tool helps measure the impact of alopecia areata on children's quality of life.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
12 citations
,
June 2021 in “Stem Cell Investigation” Aloe vera heals deep second-degree burns faster and better than mesenchymal stem cells.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
3 citations
,
July 2025 in “BMC Oral Health” The scaffold could effectively replace traditional methods for bone regeneration in dental applications.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” 6 citations
,
March 2021 in “Journal of the American Academy of Dermatology” The Brigham Eyelash Tool for Alopecia (BELA) is a reliable way to measure eyelash loss in alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
7 citations
,
October 2023 in “Journal of Intelligent & Fuzzy Systems” The new model improves Alopecia Areata classification accuracy to 93.1%.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
1 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
March 2026 in “JID Innovations” Aire mutation reduces alopecia areata, while Notch4 mutation prevents it in mice.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
1 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.
2 citations
,
July 2024 in “Materials Today Communications” The FN3-Alg hydrogel effectively heals irregular wounds and promotes hair growth.